AREXVY (recombinant, AS01E adjuvanted vaccine) - GlaxoSmithKline Inc. Authorized for the prevention of lower respiratory tract disease caused by RSV in adults 60 years of age and older. NACI is currently reviewing the use of Arexvy in older adults.
Authorized for active immunization of pregnant individuals from 32 through 36 weeks gestational age for the prevention of lower respiratory tract disease (LRTD) and severe LRTD caused by RSV in infants from birth through 6 months of age.
Authorized for the prevention of LRTD caused by RSV in individuals 60 years of age and older by active immunization.
NACI is currently reviewing the use of ABRYSVO™ in adults 60 years of age and older.
Safety and Adverse Events
Common Reactions: Injection site reactions, fever, nervousness, cough, rhinitis, and diarrhea.